Melanocortin Receptor Agonism and Feeding Behavior in Rodent Models
A 2003 study published in Endocrinology examined the interactions between Melanotan II (MT-II) and neuropeptide Y (NPY) in the regulation of feeding behavior and neuroendocrine axes in male rats. The researchers utilized intracerebroventricular (ICV) coinfusion protocols to investigate whether MT-II could modulate the orexigenic and adipogenic effects of NPY. The study assessed food intake, body weight changes, and hormonal parameters over the experimental period.
The results demonstrated that when coinfused with NPY, MT-II was able to counteract most of NPY’s effects on feeding behavior, but did not affect NPY’s suppressive effects on the gonadotropic and somatotropic axes. This dissociation provided important evidence that the neural pathways by which NPY affects growth and reproduction are distinct from those mediating feeding behavior, and that the latter pathways are sensitive to melanocortin peptide modulation while the former are not.
Citation: Pronchuk N, Beck-Sickinger AG, Bhatt DK, Colmers WF. The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. Endocrinology. 2003;144(3):931-940. doi:10.1210/en.2002-220752. PubMed PMID: 12535159
Effects on Grooming and Exploratory Behavior Following Stress Exposure
A 2008 study published in Pharmacology, Biochemistry and Behavior investigated the effects of Melanotan II on grooming and exploration behaviors in rats following repeated restraint/immobilization stress. The researchers administered MT-II intraperitoneally and observed behavioral responses in an open-field device. The study examined both naive rats and rats that had undergone repeated restraint stress to assess potential stress-modulating properties.
The findings revealed that a single dose of MT-II (2 mg/kg, i.p.) increased grooming behavior in naive rats placed in an unfamiliar open-field environment without altering locomotion or rearing activities. In rats previously subjected to repeated restraint, MT-II administration also modulated behavioral patterns. The authors interpreted these results within the context of melanocortin receptor signaling in stress-responsive brain regions, noting the involvement of central MC4R in mediating these behavioral effects.
Citation: Klenerova V, Krejci I, Sida P, Hlinak Z, Hynie S. Effects of melanotan II, a melanocortin agonist, on grooming and exploration in rats after repeated restraint/immobilization. Pharmacology, Biochemistry and Behavior. 2008;89(3):451-457. doi:10.1016/j.pbb.2008.01.017. PubMed PMID: 18191328
Thermogenic Capacity and Adipose Tissue Remodeling in Mouse Models
A 2021 study published in the Journal of Molecular Endocrinology investigated the effects of Melanotan II on thermogenic capacity and adipose tissue remodeling in PACAP-deficient (PACAP-/-) mice during cold acclimation. Female PACAP-/- and wild-type mice received daily peripheral injections of MT-II for three weeks during cold exposure, and the researchers assessed thermogenic capacity and adipose tissue changes through physiological and histological analyses.
The results demonstrated that MT-II treatment partially rescued the impaired thermogenic capacity observed in PACAP-deficient mice. The study documented changes in adipose tissue architecture consistent with browning of white adipose tissue, including increased expression of uncoupling protein 1 (UCP1). These findings provided evidence for melanocortin receptor-mediated effects on energy expenditure and adipose tissue remodeling, independent of the PACAP signaling pathway.
Citation: Szabo E, Nemeth J, Gaszner B, Berta G, Deres L, et al. Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice. Journal of Molecular Endocrinology. 2021;66(2):117-128. doi:10.1530/JME-20-0219. PubMed PMID: 33332767
Melanocortin Receptor Activation in the Nucleus Accumbens and Ingestive Behavior
A 2022 study published in Peptides investigated the effects of Melanotan II microinjection directly into the nucleus accumbens (NAcc) of mice on appetitive and consumptive responding for food. Male C57BL/6J mice received bilateral microinjections of MT-II at doses of 0.1, 0.3, and 1 nmol, and ingestive behaviors were examined in both home cage feeding and operant food self-administration paradigms.
The study demonstrated that intra-NAcc MT-II administration produced dose-dependent decreases in both appetitive and consumptive food-directed behaviors. These findings extended the understanding of melanocortin signaling beyond the hypothalamus by demonstrating a functional role for melanocortin receptors in the nucleus accumbens, a brain region traditionally associated with reward and motivation circuitry. The results suggested that melanocortin receptor signaling in mesolimbic circuits contributes to the regulation of food-motivated behavior in animal models.
Citation: Pandit R, Mercer JG, Overduin J, la Fleur SE, Adan RA. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Peptides. 2022;157:170867. doi:10.1016/j.peptides.2022.170867. PubMed PMID: 36155088
Melanocortin Peptide Therapeutics: Historical Milestones and Research Development
A 2006 review published in Peptides chronicled the historical development of melanocortin peptide research, with particular focus on the superpotent analogs Melanotan I (afamelanotide) and Melanotan II. The authors, including Mac Hadley who was instrumental in the original development of these compounds at the University of Arizona, traced the research trajectory from the initial discovery of α-MSH’s pigmentary effects through the rational design of MT-II as a cyclic, proteolytically stable analog with enhanced receptor binding affinity.
The review documented MT-II’s non-selective agonism across melanocortin receptor subtypes and discussed its utility as a pharmacological research tool for probing melanocortin receptor function in various organ systems. The authors catalogued preclinical studies in multiple animal models demonstrating MT-II’s effects on pigmentation (via MC1R), energy homeostasis (via MC3R/MC4R), and other melanocortin-mediated processes. The paper provided critical context for understanding the structure-activity relationships that informed the design of more selective melanocortin receptor ligands.
Citation: Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029. PubMed PMID: 16412534
Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.